← Back to Home

Improving Cholesterol Clearance: Editas Gene Editing Therapy Cleared for First Human Trial

EDIT-401 aims to make cholesterol lowering last longer by increasing LDL receptor expression. The required ethics review and notification procedures have been completed in Australia; the first question to address next is safety in humans.

By SURL BioNews

For patients who need further reductions in low-density lipoprotein cholesterol (LDL-C), helping the body clear cholesterol from the blood more efficiently is a treatment approach worth testing. EDIT-401, developed by Editas Medicine, aims to increase LDL receptor expression through in vivo gene editing. This concept has now been cleared to enter its first human trial.

Editas announced on October 8 that the Phase 1/2 Strive trial in patients with heterozygous familial hypercholesterolemia had received approval from an Australian Human Research Ethics Committee and completed the Australian Therapeutic Goods Administration (TGA) clinical trial notification process. This means the trial can move toward dosing; it does not mean the therapy has been approved for marketing.

EDIT-401 is designed to edit LDLR, the gene associated with the LDL receptor, to increase receptor protein expression and lower LDL-C. LDL receptors help clear cholesterol from the blood; increasing their expression is the biological basis on which this therapy hopes to establish sustained lipid lowering. However, this remains an experimental treatment, and its effects in humans have yet to be confirmed.

According to the company’s current timeline, the first patients are expected to receive doses in 2026, with initial safety and tolerability data scheduled for release in the first quarter of 2027. The trial has also been submitted for review in New Zealand; whether patients there can participate still depends on subsequent approval. These dates are all part of the development plan, rather than clinical milestones already achieved.

The first human trial will move the question from “Can receptor expression be increased?” to “Can patients safely receive this intervention?” Even if subsequent observations show a reduction in LDL-C, sufficient follow-up will still be needed to determine how long that reduction lasts, whether responses are consistent across patients, and whether delayed adverse reactions occur.

At present, this development is based primarily on the company’s announcement, with no human efficacy results yet available for evaluation. Entering clinical development is an important step for EDIT-401, but there is still a gap that trial data must fill between the biological concept of lowering cholesterol and proof that it can safely and durably improve patients’ health.

References

  1. Editas Medicine / GlobeNewswire